ESC Premium Access

Controversy: can we propose atrial fibrillation ablation as first line therapy?

Event: ESC Asia with APSC & AFC 2021
Topic: Atrial Fibrillation (AF)
Session type: Debate Session
Date: 4 December 2021
Time: 05:20 - 06:05

Congress Session

Become an ESC member to access this resource

Become a member

Already a member? Sign in

3 presentations in this session

Controversy: can we propose atrial fibrillation ablation as first line therapy? - YES.

Speaker: Associate Professor C. Ching (Singapore, SG)
Thumbnail

Controversy: can we propose atrial fibrillation ablation as first line therapy? - NO.

Speaker: Professor C. Leclercq (Rennes, FR)
Thumbnail

Controversy: can we propose atrial fibrillation ablation as first line therapy? - panel discussion.

Thumbnail

2 speakers from this session

Associate Professor Chi-Keong Ching

National Heart Centre Singapore, Singapore (Singapore)
6 presentations
0 follower

Professor Christophe Leclercq

University Hospital of Rennes - Hospital Pontchaillou, Rennes (France)
46 presentations
3 followers

Related content

ESC Premium Access

Pregnancy in women with cardiovascular disease

3 December 2021

ESC Premium Access

Current controversies in antithrombotic therapy

3 December 2021

ESC Premium Access

Opening session

2 December 2021

This platform is supported by

logo Novo Nordisk